title: A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
authors.forename: Eisaku
authors.initials: E
authors.lastname: Iwanaga
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nanri
authors.forename: Naofumi
authors.initials: N
authors.lastname: Matsuno
authors.forename: Toshiro
authors.initials: T
authors.lastname: Kawakita
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Mitsuya
authors.forename: Norio
authors.initials: N
authors.lastname: Asou
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000473:pathology; D008297:Male; D009154:Mutation; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D014178:Translocation, Genetic; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: C497970:FLT3 protein, human; D019009:Proto-Oncogene Proteins c-kit; D051941:fms-Like Tyrosine Kinase 3; D053614:Janus Kinase 2